Drug Profile
Research programme: erythropoietin receptor agonists - Viking Therapeutics
Alternative Names: EPO receptor agonists - Viking Therapeutics; LG 5640Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Neurogen Corporation
- Developer Viking Therapeutics
- Class Small molecules
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 31 Dec 2022 Viking Therapeutics receives patent allowance for erythropoietin receptor agonists Australia, Canada, China, Europe, India, Japan, Korea and the US
- 28 Jan 2022 No recent reports of development identified for preclinical development in Anaemia in USA (PO)
- 07 Jan 2020 Erythropoietin receptor agonists are still in preclinical trials for Anaemia in USA (PO)